Relapsed/Refractory Acute Myeloid Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Relapsed/Refractory Acute Myeloid Leukemia Research. Learn more about our innovative pipeline today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
• In November 2024:- Roswell Park Cancer Institute- This phase I/Ib trial studies the side effects and best dose of talazoparib given together with gemtuzumab ozogamicin and to see how well they work in treating patients with CD33 positive acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Talazoparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Gemtuzumab ozogamicin is a protein (antibody) combined with a chemotherapy drug which specifically targets acute myeloid leukemia cells expressing a marker (CD33). Adding talazoparib to the gemtuzumab ozogamicin therapy may lead to an increased effectiveness in treatment.
• In October 2024:- Astellas Pharma- The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and to determine the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants.
• In October 2024:- Sanofi- An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
• In October 2024:- Apollo Therapeutics Ltd- A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination With Azacitidine in Adults With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB)
• In October 2024:- Ryvu Therapeutics SA- The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2
• DelveInsight's Relapsed/Refractory Acute Myeloid Leukemia pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
• The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Promising Relapsed/Refractory Acute Myeloid Leukemia Therapies such as UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.

Stay informed about the cutting-edge advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatments. Download for updates and be a part of the revolution in care @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile

• APG-2575: Ascentage Pharma
APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).

• CLN 049: Cullinan Oncology
CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.

• Lanraplenib: Kronos Bio
Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.

Learn more about Relapsed/Refractory Acute Myeloid Leukemia Drugs opportunities in our groundbreaking Relapsed/Refractory Acute Myeloid Leukemia Research and development projects @ Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsed/Refractory Acute Myeloid Leukemia Market Drivers
• Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important
• factors that are fueling the Relapsed/Refractory Acute Myeloid Leukemia Market.

Relapsed/Refractory Acute Myeloid Leukemia Market Barriers
• However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Relapsed/Refractory Acute Myeloid Leukemia Market growth.

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
• Coverage- Global
• Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapies- UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Relapsed/Refractory Acute Myeloid Leukemia Pipeline on our website @ Relapsed/Refractory Acute Myeloid Leukemia Drugs and Companies- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Relapsed/refractory acute myeloid leukemia (AML): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsed/refractory acute myeloid leukemia (AML)- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. APG-2575: Ascentage Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CLN 049: Cullinan Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
21. Relapsed/refractory acute myeloid leukemia (AML) Key Products
22. Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
23. Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
24. Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
25. Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
26. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
27. Appendix

List of the Top Selling Market Research Reports in 2024

Celiac Disease Market: https://www.delveinsight.com/report-store/celiac-disease-cd-market
Coronary Stents Market: https://www.delveinsight.com/report-store/coronary-stents-market-market
CXCR Inhibitors Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
Diabetic Gastroparesis Market: https://www.delveinsight.com/report-store/gastroparesis-market
Fertility Monitoring Devices Market: https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
Phototherapies for Psoriasis Market: https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
Pipeline Assessment Services: https://www.delveinsight.com/consulting/pipeline-assessment-services
Ranibizumab Biosimilars Market: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
Rhinitis Market: https://www.delveinsight.com/report-store/rhinitis-market
Skin Grafting Devices Market: https://www.delveinsight.com/report-store/skin-grafting-devices-market
Spinal Implants Market: https://www.delveinsight.com/report-store/spinal-implants-market
Surgical Sealant Market: https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Thrombectomy Devices Market: https://www.delveinsight.com/report-store/thrombectomy-devices-market
Venous Ulcer Market: https://www.delveinsight.com/report-store/venous-leg-ulcer-market
ADHD Market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Bacterial Meningitis Market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Heart Pump Devices Market: https://www.delveinsight.com/report-store/heart-pump-device-market
Meningococcal Meningitis Market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
Pouchitis Market: https://www.delveinsight.com/report-store/pouchitis-market
Respiratory Syncytial Virus Market: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
Shingles Market: https://www.delveinsight.com/report-store/shingles-market
Artificial Disc Market: https://www.delveinsight.com/report-store/artificial-disc-market
Avascular Necrosis Market: https://www.delveinsight.com/report-store/avascular-necrosis-market
Embolotherapy Market: https://www.delveinsight.com/report-store/embolotherapy-market
Orthopedic Power Devices Market: https://www.delveinsight.com/report-store/orthopedic-power-devices-market
Perennial Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
Plaque Psoriasis Market: https://www.delveinsight.com/report-store/plaque-psoriasis-market
Psoriasis Vulgaris Market: https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
UK Healthcare Report: https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
Attention Deficit Hyperactivity Disorder Market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
Coronary Angioplasty Market: https://www.delveinsight.com/report-store/coronary-stents-market-market
NK Cell Therapy Market: https://www.delveinsight.com/report-store/nk-cell-therapy-market
Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market
Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
Attention Deficit Hyperactivity Disorder ADHD Market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Catheter Stabilization Devices Market: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
Dyspepsia Market: https://www.delveinsight.com/report-store/functional-dyspepsia-market-share
Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
Orthopedic Splints Device Market: https://www.delveinsight.com/report-store/orthopedic-splints-market
Sepsis Market: https://www.delveinsight.com/report-store/sepsis-market
Overactive Bladder Syndrome Market: https://www.delveinsight.com/report-store/overactive-bladder-market
Spinal Trauma Devices Market: https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
Temporomandibular Disorders Market: https://www.delveinsight.com/report-store/temporomandibular-disorders-market
Viscosupplementation Devices Market: https://www.delveinsight.com/report-store/viscosupplementation-devices-market
Vitreoretinal Surgery Devices Market: https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Advanced Liver Cancer Market: https://www.delveinsight.com/report-store/liver-cancer-market
Gene Therapy in CNS Disorder Market: https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
Lice Infestations Market: https://www.delveinsight.com/report-store/lice-infestations-market
Plantar Fasciitis Market: https://www.delveinsight.com/report-store/plantar-fasciitis-market
Biopsy Devices Market: https://www.delveinsight.com/report-store/biopsy-devices-market
Endoscopic Ultrasound Market: https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
Healthcare Consulting Solutions: https://www.delveinsight.com/consulting
Pelvic Organ Prolapse Market: https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Pulmonary Emphysema Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
Schistosomiasis Market: https://www.delveinsight.com/report-store/schistosomiasis-market
Testicular Neoplasm Market: https://www.delveinsight.com/report-store/testicular-neoplasm-market
Tourette Syndrome Market: https://www.delveinsight.com/report-store/tourette-syndrome-market
Wound Healing Devices Market: https://www.delveinsight.com/report-store/wound-healing-devices-market
Chronic Neuropathic Pain Market: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
Transcatheter Treatment Market: https://www.delveinsight.com/report-store/transcatheter-treatment-market
SGLT2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Surgical Lasers Market: https://www.delveinsight.com/report-store/surgical-lasers-market
Stem Cell Market: https://www.delveinsight.com/report-store/stem-cell-market
Myeloproliferative Neoplasms Market: https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
Pacemakers Market: https://www.delveinsight.com/report-store/pacemakers-market
Urea Cycle Disorders Market: https://www.delveinsight.com/blog/urea-cycle-disorder-market
Varicose Vein Treatment Devices Market: https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulator Market: https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Intraocular Lens Market: https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Lymphoedema Market: https://www.delveinsight.com/report-store/lymphedema-market
Somatotropin Deficiency Market: https://www.delveinsight.com/report-store/somatotropin-deficiency-market
Skin Neoplasm Market: https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical Mask & Respirator Market: https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Meibomian Gland Dysfunction Market: https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight
Novel Drug Delivery Devices Market: https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Total Knee Arthroplasty Market: https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Asperger Syndrome Market: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Medical Marijuana Market: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Lactose Intolerance Market: https://www.delveinsight.com/report-store/lactose-intolerance-market
Microscopy Device Market: https://www.delveinsight.com/sample-request/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.